England’s Innovative Medicines Fund is aimed at providing earlier access to promising new treatments, including gene therapies, when further data is needed for routine commissioning.

England’s health technology assessment body NICE did not recover costs for technology appraisals through fees thanks to the COVID-19 pandemic.

Reimbursement timelines in Italy and France for the treatments in question have been quicker than the average.

An initiative that will improve payers’ ability to negotiate prices for disruptive new drugs is closer to fruition.

Environmental criteria in tendering could lead to short term cost increases but long-term savings for pharmaceutical companies.

Companies that are in earlier stages of the drug development process will benefit most from the UK regulator's new pathway for innovative medicines.